Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.

Lung cancer (Amsterdam, Netherlands) - 1 Jul 2010

Kalikaki Aristea, Koutsopoulos Anastasios, Hatzidaki Dora, Trypaki Maria, Kontopodis Emmanouel, Stathopoulos Efstathios, Mavroudis Dimitris, Georgoulias Vassilis, Voutsina Alexandra

Abstract excerpt

BACKGROUND: Somatic mutations in EGFR and K-RAS may predict for sensitivity and resistance to EGFR tyrosine kinase inhibitors (TKIs). Whether EGFR and K-RAS mutations could also predict clinical outcome of non-small cell lung cancer (NSCLC) patients following front-line chemotherapy has not yet b...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Survival Analysis

Share to Treatment Outcome

Source

Identifiers

PMID: 19854533
DOI: 10.1016/j.lungcan.2009.09.010

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19854533-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.PMID 19854533Read ↗

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.Semantic proximity Read ↗

Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.Semantic proximity Read ↗

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.Semantic proximity Read ↗

Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?Semantic proximity Read ↗

NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.Semantic proximity Read ↗

EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.Semantic proximity Read ↗

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.Semantic proximity Read ↗

[Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.